In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
News|Podcasts|April 3, 2026
ACT Brief: Digital Twins for Virtual Control Arms, Clinical Tech Stack Evolution, and Universal Flu Vaccine Advances
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we explore how digital twin technology creates reliable virtual control arms from historical data, what defines an effective clinical trial tech stack in complex studies, and emerging vaccine platforms advancing toward universal influenza protection.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In a new contributed
article , researchers demonstrated that digital twin technology can construct virtual standard-of-care arms from historical clinical trial data, reducing recruitment burden and addressing ethical concerns around placebo designs. A digital twin cohort of left-sided RAS wild-type metastatic colorectal cancer patients showed stable efficacy outcomes across cohorts, validating the potential for DT integration across drug discovery and trial conduct. - In a new
Q&A , Cheryl Kole, vice president of solution strategy and commercialization at Almac Clinical Technologies, discussed what defines an effective modern tech stack: purpose-built tools that integrate seamlessly, guide users through workflows, and simplify execution rather than add complexity. The biggest gap in current systems is insufficient workflow guidance for busy sites managing multiple trials simultaneously. - In a new
interview from Pharmaceutical Executive, Christopher Locher, PhD, CEO of Versatope Therapeutics, discussed emerging vaccine platforms advancing toward a universal influenza vaccine. Multiple approaches including nanoparticle scaffolds, integrated immunity strategies, and epitope-focusing designs are progressing through development, though challenges remain around correlates of protection, development costs, and regulatory expectations.
That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
In today's ACT Brief, we examine what patient-site relationships need beyond easier technology, how to build defensible rare disease evidence from scratch, and how real-world data and AI improve enrollment screening accuracy.
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site readiness requires as therapy moves to community care, and why data harmonization is AI's primary bottleneck.
Trending on Applied Clinical Trials Online
1
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
2
Hierarchical Endpoints in Cardiology: How Much Treatment Benefit, and From Where
3
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
4
What ClinOps Professionals Just Starting With AI Should Keep Top of Mind
5